AMENDMENTS TO THE CLAIMS

1. (**currently amended**) A method of treating a mammal having pollakiuria or urinary incontinence wherein pollakiuria and urinary incontinence is not responsive to COX-2 inhibition ~~opening a large conductance calcium activated K channel in a mammal in need thereof~~, said method comprising administering to said mammal a compound of the formula (I):



(I)

wherein R^1 is a halogen, aminosulfonyl, an alkylsulfonyl or an alkanoylaminosulfonyl; R^2 is hydrogen or a halogen; R^3 and R^4 may be the same or different from each other and each is hydrogen, a halogen, an alkyl or an alkoxy; Ring A is benzene, pyridine or a cycloalkane, and Ring Q is



where R^5 is a halogen, an alkyl or a haloalkyl; R^6 is hydrogen or an alkyl; or R^5 and R^6 may be combined to each other to form oxo; ~~R^7 and R^8 are hydrogen or may be combined to each other to form oxo; and R^9 is a carboxyalkyl~~,

~~or Ring Q and Ring A may be combined to each other to form a fused ring of the formula:~~



~~where X is sulfur or oxygen, and R^3, R^4 and R^5 have the same meanings as defined above,~~

or a pharmaceutically acceptable salt thereof as an active

ingredient.

2. (**currently amended**) The method according to Claim 1, wherein the compound is a compound of the formula (II):



(II)

wherein R^{1a} is amino, an alkyl or an alkanoylamino; R^2 is hydrogen or a halogen; R^3 and R^4 may be the same or different from each other and each is hydrogen, a halogen, an alkyl or an alkoxy; Ring A' is benzene or a cycloalkane, and Ring Q' is



where R^5 is a halogen, an alkyl or a haloalkyl; R^6 is hydrogen or an alkyl; or R^5 and R^6 may be combined to each other to form oxo,

or a pharmaceutically acceptable salt thereof as an active ingredient.

3. (**currently amended**) The method according to Claim 1, wherein the compound is a compound selected from the group consisting of:

(1) celecoxib,

~~(2) rofecoxib,~~

(3) valdecoxib,

(4) parecoxib,

(5) tilmacoxib,

(6) 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide,

~~(7) 2-(3,5-difluorophenyl)-3-(4-methylsulfonylphenyl)-2-cyclopenten-1-one,~~

~~(8) 1-fluoro-4-(2-(4-methylsulfonylphenyl)-1-cyclopenten-1-yl)benzene,~~

(9) 4-(5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl)benzenesulfonamide,

(10) 4-(2-methyl-4-phenyloxazol-5-yl)benzenesulfonamide,

(11) 4-(2-oxo-3-phenyl-2,3-dihydroxazol-4-yl)benzenesulfonamide,

~~(12) 1-(3,3-dimethyl-5-(4-methylsulfonylphenyl)cyclopenta-1,4-dien-1-yl)-4-fluorobenzene,~~

~~(13) 4-(2-(4-methoxyphenyl)-4-methylpyrrol-1-yl)benzene-sulfonamide,~~

~~(14) etoricoxib,~~

~~(15) 4,4-dimethyl-2-phenyl-3-(4-methylsulfonylphenyl)cyclo-butanone,~~

~~(16) 5-(4-methylsulfonylphenyl)-6-phenyl[1,3]thiazole[3,2-b][1,2,4]triazole,~~

~~(17) 4-(6-fluoro-7-methoxy-3-trifluoromethylisothiochromeno[4,3-c]pyrazol-1(5H)-yl)benzenesulfonamide,~~

(18) licofelone,

(19) 4-[5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(20) N-acetyl-4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(21) 4-[5-(4-methylphenyl)-3-chloromethyl-1H-pyrazol-1-yl]-benzenesulfonamide,

(22) 4-[5-(4-methylphenyl)-3-methyl-1H-pyrazol-1-yl]benzenesulfonamide,

(23) 4-[5-(2-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(24) 4-[5-(3-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(25) 4-[5-(2-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(26) 4-[5-(3-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(27) 4-[5-(4-methylphenyl)-3-n-propyl-1H-pyrazol-1-yl]benzenesulfonamide,

(28) 4-[5-(4-methylphenyl)-3-ethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(29) 4-[5-(4-methylphenyl)-3-isopropyl-1H-pyrazol-1-yl]benzenesulfonamide,

(30) 4-[5-phenyl-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(31) 4-[5-(2-methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(32) 4-[5-(3-methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(33) 4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(34) 4-[5-(3-fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(35) 4-[5-(4-fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(36) 4-[5-(2-fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(37) 4-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(38) 5-(4-methylphenyl)-1-(4-methylsulfonylphenyl)-3-trifluoromethyl-1H-pyrazole,

(39) 5-(4-methylphenyl)-1-(4-fluorophenyl)-3-trifluoromethyl-1H-pyrazole,

(40) 5-(4-methylphenyl)-1-(3-chlorophenyl)-3-trifluoromethyl-1H-pyrazole,

(41) 5-(4-methylphenyl)-1-(2-chlorophenyl)-3-trifluoromethyl-1H-pyrazole,

(42) 5-(4-methylphenyl)-1-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazole,

(43) 4-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(44) 4-[5-(3-pyridyl)-3-trifluoromethyl-1H-pyrazol-1-yl]-benzenesulfonamide,

(45) 4-[5-methyl-3-(4-bromophenyl)isoxazol-4-yl]benzene-sulfonamide, and

(46) 5-methyl-3-phenyl-4-(4-methylsulfonylphenyl)isoxazole,

or a pharmaceutically acceptable salt thereof as an active ingredient.

4. (**currently amended**) The method according to Claim 1, wherein the compound is a compound selected from the group consisting of:

(1) celecoxib,

~~(2) rofecoxib,~~

(3) valdecoxib,

(4) parecoxib,

(5) tilmacoxib,

(6) 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide,

(9) 4-(5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl)benzenesulfonamide,

(10)4-(2-methyl-4-phenyloxazol-5-yl)benzenesulfonamide, and

(11) 4-(2-oxo-3-phenyl-2,3-dihydroxazol-4-yl)benzenesulfonamide,

~~(21) 4-[5-(4-methylphenyl)-3-chloromethyl-1H-pyrazol-1-yl]benzenesulfonamide,~~

~~(22) 4-[5-(4-methylphenyl)-3-methyl-1H-pyrazol-1-yl]benzenesulfonamide,~~

~~(23)4-[5-(2-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,~~

~~(36) 4-[5-(2-fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,~~

~~(37) 4-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,~~

~~(43) 4-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,~~

~~(44) 4-[5-(3-pyridyl)-3-trifluoromethyl-1H-pyrazol-1-yl]-benzenesulfonamide, and~~

~~(45) 4-[5-methyl-3-(4-bromophenyl)isoxazol-4-yl]benzene-sulfonamide,~~

or a pharmaceutically acceptable salt thereof as an active

ingredient.

5. (**currently amended**) The method according to ~~any one of Claims 1 to 4, wherein the mammal has pollakiuria or urinary incontinence.~~ Claim 1, wherein the compound is a compound selected from the group consisting of:

(1) celecoxib,

(3) valdecoxib,

(4) parecoxib, and

(5) tilmacoxib.

6. (**New**) A method of treating a mammal having pollakiuria comprising administering to said mammal celecoxib or a pharmaceutically acceptable salt thereof as an active ingredient.

7. (**New**) A method of treating a mammal having pollakiuria or urinary incontinence by opening a large conductance calcium-activated K channel, said method comprising administering to said mammal a compound of the formula (I):



(I)

wherein R^1 is a halogen, aminosulfonyl, an alkylsulfonyl or an alkanoylaminosulfonyl; R^2 is hydrogen or a halogen; R^3 and R^4 may be the same or different from each other and each is hydrogen, a halogen, an alkyl or an alkoxy; Ring A is benzene, pyridine or a cycloalkane, and Ring Q is



where R^5 is a halogen, an alkyl or a haloalkyl; R^6 is hydrogen or an alkyl; or R^5 and R^6 may be combined to each other to form oxo,

or a pharmaceutically acceptable salt thereof as an active ingredient, wherein said pollakiuria and urinary incontinence is treatable solely by opening said large conductance calcium-activated K channel.

8. (**New**) The method according to Claim 7, wherein the compound is a compound of the formula (II):



(II)

wherein R^{1a} is amino, an alkyl or an alkanoylamino; R^2 is hydrogen or a halogen; R^3 and R^4 may be the same or different from each other and each is hydrogen, a halogen, an alkyl or an alkoxy; Ring A' is benzene or a cycloalkane, and Ring Q' is



where R^5 is a halogen, an alkyl or a haloalkyl; R^6 is hydrogen or an alkyl; or R^5 and R^6 may be combined to each other to form oxo,

or a pharmaceutically acceptable salt thereof as an active ingredient.

9. (**New**) The method according to Claim 7, wherein the compound is a compound selected from the group consisting of:

(1) celecoxib,

(3) valdecoxib,

(4) parecoxib,

(5) tilmacoxib,

(6) 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide,

(9) 4-(5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl)benzenesulfonamide,

(10) 4-(2-methyl-4-phenyloxazol-5-yl)benzenesulfonamide,

(11) 4-(2-oxo-3-phenyl-2,3-dihydroxazol-4-yl)benzenesulfonamide,

(18) licofelone,

(19) 4-[5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(20) N-acetyl-4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(21) 4-[5-(4-methylphenyl)-3-chloromethyl-1H-pyrazol-1-yl]-benzenesulfonamide,

(22) 4-[5-(4-methylphenyl)-3-methyl-1H-pyrazol-1-yl]benzenesulfonamide,

(23) 4-[5-(2-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(24) 4-[5-(3-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(25) 4-[5-(2-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(26) 4-[5-(3-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(27) 4-[5-(4-methylphenyl)-3-n-propyl-1H-pyrazol-1-yl]benzenesulfonamide,

(28) 4-[5-(4-methylphenyl)-3-ethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(29) 4-[5-(4-methylphenyl)-3-isopropyl-1H-pyrazol-1-yl]benzenesulfonamide,

(30) 4-[5-phenyl-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(31) 4-[5-(2-methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(32) 4-[5-(3-methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(33) 4-[5-(4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(34) 4-[5-(3-fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(35) 4-[5-(4-fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(36) 4-[5-(2-fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(37) 4-[5-(3,4-dimethoxyphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(38) 5-(4-methylphenyl)-1-(4-methylsulfonylphenyl)-3-trifluoromethyl-1H-pyrazole,

(39) 5-(4-methylphenyl)-1-(4-fluorophenyl)-3-trifluoromethyl-1H-pyrazole,

(40) 5-(4-methylphenyl)-1-(3-chlorophenyl)-3-trifluoromethyl-1H-pyrazole,

(41) 5-(4-methylphenyl)-1-(2-chlorophenyl)-3-trifluoromethyl-1H-pyrazole,

(42) 5-(4-methylphenyl)-1-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazole,

(43) 4-[5-(3,4-dimethylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide,

(44) 4-[5-(3-pyridyl)-3-trifluoromethyl-1H-pyrazol-1-yl]-benzenesulfonamide,

(45) 4-[5-methyl-3-(4-bromophenyl)isoxazol-4-yl]benzene-sulfonamide, and

(46) 5-methyl-3-phenyl-4-(4-methylsulfonylphenyl)isoxazole,

or a pharmaceutically acceptable salt thereof as an active ingredient.

10. (**New**) The method according to Claim 7, wherein the compound is a compound selected from the group consisting of:

(1) celecoxib,

(3) valdecoxib,

(4) parecoxib,

(5) tilmacoxib,

(6) 4-(4-chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-yl)benzenesulfonamide,

(9) 4-(5-(4-chlorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl)benzenesulfonamide,

(10) 4-(2-methyl-4-phenyloxazol-5-yl)benzenesulfonamide, and

(11) 4-(2-oxo-3-phenyl-2,3-dihydroxazol-4-yl)benzenesulfonamide,

or a pharmaceutically acceptable salt thereof as an active ingredient.

11. (**New**) The method according to Claim 7, wherein the compound is a compound selected from the group consisting of:

(1) celecoxib,

(3) valdecoxib,

(4) parecoxib, and

(5) tilmacoxib.